Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 7, 2014, to announce its financial results for the quarter ended June 30, 2014. This filing primarily serves to furnish the press release containing these financial details. Investors should note that the information provided in this 8-K, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability as a formally filed document. While the 8-K itself is brief, the accompanying press release (Exhibit 99.1) is where the substantive financial and operational updates for the period would be found. Investors would need to refer to that exhibit for specific details regarding revenue, expenses, cash flow, and any forward-looking statements or business developments announced by Alnylam during that quarter. The report confirms the date of the announcement of these results, which is a standard disclosure practice.
Key Highlights
- 1Alnylam Pharmaceuticals announced its financial results for the second quarter of 2014 on August 7, 2014.
- 2The 8-K filing serves as the official notification of these quarterly results.
- 3The press release detailing the financial results is furnished as Exhibit 99.1 to this filing.
- 4Information furnished in this 8-K is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934.
- 5This filing is primarily a procedural disclosure of the earnings announcement.
- 6Investors should consult the furnished press release (Exhibit 99.1) for specific financial and operational details.